STATE OF CONNECTICUT

REGULATION

of the

DEPARTMENT OF CONSUMER PROTECTION

(NAME OF AGENCY)

concerning

CONTROLLED SUBSTANCES

(SUBJECT MATTER OF REGULATION)

2011 JUN 10 AM 11:57
SECRETARY OF THE STATE
LEGISLATION & ELECTIONS
ADMINISTRATION DIVISION

Section 1. Section 21a-243-7 of the Regulations of Connecticut State Agencies is amended to read as follows:

The controlled substances listed in this regulation are included by whatever official, common, usual, chemical, or trade name designation in Schedule I:

(a) Any of the following opiates, including their isomers, esters, ethers, salts and salts of isomers, esters and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation:

(1) Acetylalpha-methylfentanyl;
(2) Acetylmethadol;
(3) Allylprodine;
(4) Alphacetylmethadol (except Levo-alphacetylmethadol or LAAM);
(5) Alphameprodine;
(6) Alphamethadol;
(7) Alpha-methylfentanyl;
(8) Alphamethylthiofentanyl;
(9) Benzethidine;
[(10) Benzylfentanyl;]
[(11)] (10) Betacetylmethadol;
[(12)] (11) Beta-hydroxy-fentanyl;
[(13)] (12) Beta-hydroxy-3-methylfentanyl;
[(14)] (13) Betameprodine;
[(15)] (14) Betamethadol;
[(16)] (15) Betaprodine;
[(17)] (16) Clonitazene;
[(18)] (17) Dextromoramide;
[(19)] (18) Diampromide;
[(20)] (19) Diethylthiambutene;
[(21)] (20) Difenoxin;
[(22)] (21) Dimenoxadol;
[(23)] (22) Dimepheptanol;
[(24)] (23) Dimethylthiambutene;
[(25)] (24) Dioxaphetyl Butyrate;
[(26)] (25) Dipipanone;
[(27)] (26) Ethylmethylthiambutene;
[(28)] (27) Etonitazene;
[(29)] (28) Etoxeridine;
[(30)] (29) Furethidine;
[(31)] (30) Hydroxypethidine;
[(32)] (31) Ketobemidone;
[(33)] (32) Levomoramide;
[(34)] (33) Levophenacylmorphan;
[(35)] (34) 3-methylfentanyl;
[(36)] (35) 3-methylthiofentanyl;
[(37)] (36) Morpheridine;
[(38)] (37) Noracymethadol;
[(39)] (38) Norlevorphanol;
[(40)] (39) Normethadone;
[(41)] (40) Norpipanone;
[(42)] (41) Para-fluorofentanyl;

(42) PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);
(43) Phenadoxone;
(44) Phenampromide;
(45) Phenomorphan;
(46) Phenoperidine;
(47) Piritramide;
(48) Proheptazine;
(49) Properidine;
(50) Propiram;
(51) Racemoramide;
[(52) Thenylfentanyl;]
[(53)] (52) Thiofentanyl;
[(54)] (53) Tilidine;
[(55)] (54) Trimeperidine.

(b) Any of the following opium derivatives, their salts, isomers and salts of isomers, unless specifically excepted whenever the existence of these salts, isomers and salts of isomers is possible within the specific chemical designation:
(1) Acetorphine;
(2) Acetyldihydrocodeine;
(3) Benzylmorphine;
(4) Codeine methylbromide;
(5) Codeine-N-oxide;
(6) Cyprenorphine;
(7) Desomorphine;
(8) Dihydromorphine;
(9) Drotebanol;
(10) Etorphine, except hydrochloride salts;
(11) Heroin;
(12) Hydromorphinol;
(13) Methyldesorphine;
(14) Methyldihydromorphine;
(15) Morphine methylbromide;
(16) Morphine methylsulfonate;
(17) Morphine-N-oxide;
(18) Myrophine;
(19) Nicocodeine;
(20) Nicomorphine;
(21) Normorphine;
(22) Pholcodine;
(23) Thebacon.

(c) Any material, compound, mixture or preparation which contains their salts, isomers and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation:
(1) Alpha-ethyltryptamine;
[(1)] (2) 4-bromo-2,5-dimethoxyamphetamine; or 4-bromo-2,5-DMA;
[(2)] (3) 2,5-dimethoxyamphetamine; or 2,5-DMA;
[(3)] (4) 2,5-Dimethoxy-4-ethylamphetamone or DOET;
[(4)] (5) 3,4-M ethylenedioxy-N-ethylamphetamine;
[(5)] (6) 1-methyl-4-phenyl-4-propionoxypiperidine; or MPPP;
[(6)] (7) 3,4-methylenedioxymethamphetamine; or MDMA;
(8) 2,5-dimethoxy-4-(n)-propylthiopenenthylamine (2C-T-7);
[(7)] (9) 4-methoxyamphetamine; or PMA;
[(8)] (10) 5-methoxy-3,4-methylenedioxy-amphetamine;
[(9)] (11) 5-Methoxy-nn-Diisopropyltryptamine(5-methoxy-dipt);
[(10)] (12) 4-methyl-2,5-dimethoxyamphetamine; or DOM; or STP
[(11)] (13) 3,4-methylenedioxy amphetamine; or MDA;
(14) N-hydroxy-3,4-methylenedioxyamphetamine (also known as N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine, and N-hydroxy MDA;
[(12)] (15) 3,4,5-trimethoxy amphetamine;
[(13)] (16) benzylpiperazine or BZP;

[(14)] (17) Bufotenine or Mappine;
[(15)] (18) Alphaethyltryptamine;
[(16)] (19) Diethyltryptamine or DET;
[(17)] (20) Dimethyltryptamine or DMT;
[(18)] (21) Ibogaine;
[(19)] (22) Lysergic acid diethylamide;
[(20)] (23) Marihuana;
[(21)] (24) Mescaline;
[(22)] (25) Parahexyl or Synhexyl;
[(23)] (26) Peyote, meaning all parts of the plants;
[(24)] (27) 1-(2-phenylethyl)-4-phenyl-4-acetoxypiperidine; or PEPAP;
[(25)] (28) N-ethyl-3-piperidyl benzilate;
[(26)] (29) N-methyl-3-piperidyl benzilate;
[(27)] (30) Psilocybin;
[(28)] (31) Psilocyn;
[(29)] (32) Tetrahydrocannabinols except Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a United States food and drug administration approved product;
[(30)] (33) Ethylamine analog of phencyclidine, Cyclohexamine or PCE;
[(31)] (34) 4-Bromo-2,5-dimethoxyphenethylamine;
[(32)] (35) Pyrrolidine analog of phencyclidine, PCP or PHP;
[(33)] (36) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine;
[(34)] (37) Thiophene analog of phencyclidine, TPCP or TCP.
[(35)] (38) Tiletamine or 2-(ethylamino)-2-(2-thienyl)-cyclohexanone;
[(36)] (39) Trifluoromethylphenylpiperazine or TFMPP.

(d) Any material, compound, mixture or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, their salts, isomers and salts of isomers unless specifically excepted, wherever the existence of these salts, isomers and salts of isomers is possible within the specific chemical designation:

(1) Gamma-hydroxy butyric acid, except if contained in a drug product for which an application has been approved under section 505 of the federal food, drug and cosmetic act;
(2) Gamma-butyrolactone;
(3) Mecloqualone;
(4) Methaqualone; or
(5) Zolazepam.

(e) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers:

(1) Aminorex;
(2) N-benzylpiperazine (some other names: BZP; 1-benzylpiperazine);
[(2)] (3) 4-Methylaminorex;
[(3)] (4) Cathinone;
[(4)] (5) Fenethylline;
[(5)] (6) Methcathinone;
[(6)] (7) N-ethylamphetamine;
[(7)] (8) N,N-Dimethylamphetamine.

Sec. 2. Section 21a-243-8 of the Regulations of Connecticut State Agencies is amended to read as follows:

The controlled substances listed in this regulation are included by whatever official, common, usual, chemical, or trade name designation in Schedule II:

(a) Any of the following substances, except those narcotic drugs listed in other schedules, whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by combination of extraction and chemical synthesis:

(1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate excluding Apomorphine, Dextrorphan, Nalbuphine, Naloxone, Naltrexone, and their salts, but including the following: Raw opium, opium extracts, opium fluid extracts, powdered opium, granulated opium, tincture of opium, codeine, dihydroetorphine, ethylmorphine, etorphine hydrochloride, hydrocodone, hydromorhone, metopon, morphine, oripavine, oxycodone, oxymorphone and thebaine;

(2) any salt, compound,isomer, derivative or preparation thereof which is chemically equivalent or identical with any of the substances referred to in paragraph (1), but not including the isoquinoline alkaloids of opium;

(3) opium poppy and poppy straw;

(4) coca leaves and any salt, compound, derivative, or preparation of coca leaves, and any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical with any of these substances, but not including decocainized coca leaves or extractions which do not contain cocaine or ecgonine;

(5) concentrate of poppy straw (the crude extract of poppy straw in either liquid, solid or powder form which contains the phenanthrine alkaloids of opium poppy).

(b) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation, Dextrorphan and Levopropoxyphene excepted:

(1) Alfentanil;
(2) Alphaprodine;
(3) Anileridine;
(4) Bezitramide;
(5) bulk Dextropropoxyphene (nondosage forms);
(6) Carfentanil;
(7) Dihydrocodeine;
(8) Diphenoxylate;
(9) Fentanyl;
(10) Isomethadone;
(11) Levo-alphacetylmethadol or LAAM;
(12) Levomethorphan;
(13) Levorphanol;
(14) Metazocine;
(15) Methadone;
(16) Methadone-intermediate,4-cyano-2-dimethylamino-4,4- diphenylbutane;
(17) Moramide-Intermediate,2-methyl-3-morpholino-1,1-diphenyl-propane-carboxylic acid;
(18) Pethidine (Meperidine);
(19) Pethidine-Intermediate-A,4-cyano-1-methyl-4-phenylpiperidine;
(20) Pethidine-Intermediate-B,ethyl-4-phenylpiperidine-4- carboxylate;
(21) Pethidine-Intermediate-C, 1-methyl 4-phenylpiperidine-4-carboxylic acid;
(22) Phenazocine;
(23) Piminodine;
(24) Racemethorphan;
(25) Racemorphan;
(26) Remifentanil;
(27) Sufentanil[.] ;
(28) Tapentadol.

(c) Unless excepted or placed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a potential for abuse associated with a stimulant effect on the central nervous system:

(1) Amphetamine, its salts, optical isomers, and salts of its optical isomers;

(2) any substance which contains any quantity of methamphetamine, including its salts, isomers, and salts of isomers;

(3) Methylphenidate;

(4) Phenmetrazine and its salts[.] ;

(5) Lisdexamfetamine and its salts, isomers and salts of isomers.

(d) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances

having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

(1) Amobarbital;
(2) Glutethimide;
(3) Pentobarbital;
(4) Phencyclidine; and
(5) Secobarbital.

(e) Hallucinogenic Substances:
(1) Nabilone.

(f) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances:

(1) Immediate precursor to Amphetamine and Methamphetamine; Phenylacetone (some trade names or other names); phenyl-2-propanone; P2P; benzyl methyl ketone; methyl benzyl ketone;

(2) immediate precursors to phencyclidine (PCP);

[(i)] (A) 1-phencylohexylamine;

[(ii)] (B) 1-piperidinocyclohaxanecarbonitrile (PCC).

Sec. 3. Section 21a-243-9 of the Regulations of Connecticut State Agencies is amended to read as follows:

The controlled substances listed in this regulation are included by whatever official, common, usual, chemical, or trade name designation in Schedule III:

(a) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

(1) Benzphetamine;
(2) Chlorphentermine;
(3) Clortermine;
(4) Phendimetrazine.

(b) Unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances having a potential for abuse associated with a depressant effect on the central nervous system:

(1) Any compound, mixture or preparation containing: Amobarbital, Secobarbital, Pentobarbital or any salt thereof and one or more other active medicinal ingredients which are not listed in any schedule;

(2) Any suppository dosage form containing Amobarbital, Secobarbital, Pentobarbital or any salt of any of these drugs and approved by the Food and Drug Administration for marketing only as a suppository;

(3) Any substance which contains any quantity of a derivative of barbituric acid, or any salt of a derivative of barbituric acid, except those substances which are specifically listed in other schedules, except that the following analgesic products shall not be considered to be controlled substances:

(A) Products containing a ratio of fifteen milligrams of long or intermediate acting barbiturates combined with at least one of the following:

(i) 188 mg aspirin;
(ii) 375 mg salicylamide; or
(iii) 70 mg phenacetin, acetanilid or acetaminophen;

(B) Products containing a ratio of fifteen milligrams of short acting barbiturates combined with at least one of the following:

(i) 307 mg aspirin;
(ii) 614 mg salicylamide; or
(iii) 106 mg phenacetin, acetanilid or acetaminophen;

(4) Any compound, mixture or preparation containing equal weights of both tiletamine and zolazepam or any salt thereof and not mixed with other psychoactive substances;

(5) Chlorhexadol;

(6) Embutramide;

[6] (7) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a United States Food and Drug Administration approved drug product;

[7] (8) Ketamine or any salt thereof;

[8] (9) Lysergic acid;

[9] (10) Lysergic acid amide;

[10] (11) Methyprylon;

[11] (12) Sulfondiethylmethane;

[12] (13) Sulfonethylmethane;

[13] (14) Sulfonmethane.

(c) Buprenorphine.

(d) Nalorphine.

(e) Any material, compound, mixture or preparation containing limited quantities of any of the following narcotic drugs or any salts thereof:

(1) Not more than 1.8 grams of codeine, or any of its salts, per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium;

(2) not more than 1.8 grams of codeine, or any of its salts, per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;

(3) not more than 300 milligrams of dihydrocodeinone, or any of its salts, per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium;

(4) not more than 300 milligrams of dihydrocodeinone, or any of its salts, per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;

(5) not more than 1.8 grams of dihydrocodeine, or any of its salts, per 100 milliliters or not more than 90 milligrams per dosage unit,with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;

(6) not more than 300 milligrams of ethylmorphine, or any of its salts, per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more ingredients in recognized therapeutic amounts;

(7) not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not more than 25 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;

(8) not more than 50 milligrams of morphine, or any of its salts, per 100 milliliters or per 100 grams with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.

(f) Unless expressly intended for administration through implants to nonhuman species and approved for such use by the Federal Food and Drug Administration, any anabolic steroid including but not limited to, any of the following, or any isomer, ester, salt or derivative of the following that acts in the same manner on the human body:

(1) 3[beta],17-dihydroxy-5a-androstane;

(2) 3[alpha],17[beta]-dihydroxy-5a-androstane;

(3) 5[alpha]-androstan-3,17-dione;

(4) 1-androstenediol (3[beta],17[beta]-dihydroxy-5[alpha]-androst-1- ene);

(5) 1-androstenediol (3[alpha],17[beta]-dihydroxy-5[alpha]-androst-1- ene);

(6) 4-androstenediol (3[beta],17[beta]-dihydroxy-androst-4-ene);

(7) 5-androstenediol (3[beta],17[beta]-dihydroxy-androst-5-ene);

(8) 1-androstenedione ([5[alpha]]-androst-1-en-3,17-dione);

(9) 4-androstenedione (androst-4-en-3,17-dione);

(10) 5-androstenedione (androst-5-en-3,17-dione;

[1] (11) Boldenone;

(12) Boldione;

[2] (13) Chlorotestosterone;
[3] (14) Clostebol;
[4] (15) Dehydrochlormethyltestosterone;
(16) [Delta]1-dihydrotestosterone (a.k.a. '1-testosterone') (17[beta]- hydroxy-5[alpha]-androst-1-en-3-one);
(17) desoxymethltestosterone;
[5] (18) Dihydrotesterone;
[6] (19) Drostanolone;
[7] (20) Ethylestrenol;
[8] (21) Fluoxymesterone;
[9] (22) Formebulone;
(23) Furazabol (17[alpha]-methyl-17[beta]-hydroxyandrostano[2,3-c]- furazan);
(24) 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one;
(25) 4-hydroxytestosterone (4,17[beta]-dihydroxy-androst-4-en-3-one);
(26) 4-hydroxy-19-nortestosterone (4,17[beta]-dihydroxy-estr-4-en-3- one);
(27) Mestanolone (17[alpha]-methyl-17[beta]-hydroxy-5-androstan-3- one);
[10] (28) Mesterolone;
[11] (29) Methandienone;
[12] (30) Methandranone;
[13] (31) Methandriol;
[14] (32) Methandrostenolone;
[15] (33) Methenolone;
(34) 17[alpha]-methyl-3[beta], 17[beta]-dihydroxy-5a-androstane;
(35) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy-5a-androstane;
(36) 17[alpha]-methyl-3[beta],17[beta]-dihydroxyandrost-4-ene;
(37) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]-methyl-4- hydroxy-17[beta]-hydroxyestr-4-en-3-one);
(38) Methyldienolone (17[alpha]-methyl-17[beta]-hydroxyestra-4,9(10)- dien-3-one);
(39) Methyltrienolone (17[alpha]-methyl-17[beta]-hydroxyestra-4,9- 11-trien-3-one);
[16] (40) Methyltesterone;
[17] (41) Mibolerone;
(42) 17[alpha]-methyl-[Delta]1-dihydrotestosterone (17b[beta]- hydroxy-17[alpha]-methyl-5[alpha]-androst-1-en-3-one) (a.k.a. '17- [alpha]-methyl-1-testosterone');
[18] (43) Nandrolone;
(44) 19-nor-4,9 (10)-androstadienedione;
(45) 19-nor-4-androstenediol (3[beta], 17[beta]-dihydroxyestr-4-ene);
(46) 19-nor-4-androstenediol (3[alpha], 17[beta]-dihydroxyestr-4-ene);
(47) 19-nor-5-androstenediol (3[beta], 17[beta]-dihydroxyestr-5-ene);
(48) 19-nor-5-androstenediol (3[alpha], 17[beta]-dihydroxyestr-5-ene);
(49) 19-nor-4-androstenedione (estr-4-en-3,17-dione);
(50) 19-nor-5-androstenedione (estr-5-en-3,17-dione;
(51) Norbolethone (13[beta], 17[alpha]-diethyl-17[beta]-hydroxygon- 4-en-3-one);
(52) Norclostebol (4-chloro-17[beta]-hydroxyestr-4-en-3-one);
[19] (53) Norethandrolone;
(54) Norethandrolone (17[alpha]-ethyl-17[beta]-hydroxyestr-4-en-3- one);
(55) Normethandrolone (17[alpha]-methyl-17[beta]-hydroxyestr-4-en-3-one);
[20] (56) Oxandrolone;
[21] (57) Oxymesterone;
[22] (58) Oxymetholone;
(59) Stenbolone (17[beta]-hydroxy-2-methyl-[5[alpha]]-androst-1-en-3- one);
[23] (60) Stanolone;
[24] (61) Stanozolol;
[25] (62) Testolactone;
[26] (63) Testosterone;
(64) Tetrahydrogestrinone (13[beta], 17[alpha]-diethyl-17[beta]- hydroxygon-4,9,11-trien-3-one);
[27] (65) Trenbolone.

(g) Chorionic gonadotropin.

(h) Any quantity of the following substances having a depressant effect on the central nervous system, including their salts, isomers and salts of such isomers, and esters:

(1) Gamma-hydroxy butyric acid if contained in a product for which an application has been approved under section 505 of the federal food, drug and cosmetic act; or

(2) Gamma-butyrolactone.

Sec. 4. Section 21a-243-10 of the Regulations of Connecticut State Agencies is amended to read as follows:

The controlled substances listed in this regulation are included by whatever official, common, usual, chemical, or trade name designation in Schedule IV:

(a) Any material, compound, mixture or preparation which contains any quantity of the following substances having a potential for abuse associated with a depressant effect on the central nervous system:

(1) Alprazolam;
(2) Barbital;
(3) Bromazepam;
(4) Camazepam;
(5) Carisoprodol;
[5] (6) Chloral betaine;
[6] (7) Chloral hydrate;
[7] (8) Chlordiazepoxide;
[8] (9) Clobazam;
[9] (10) Clonazepam;
[10] (11) Clorazepate;
[11] (12) Clotiazepam;
[12] (13) Cloxazolam;
[13] (14) Delorazepam;
[14] (15) Diazepam;
[15] (16) Dochloralphenazone;
[16] (17) Estazolam;
[17] (18) Etholorvynol;
[18] (19) Ethinamate;
[19] (20) Ethyl-lofiazepate;
[20] (21) Fludiazepam;
[21] (22) Flunitrazepam;
[22] (23) Flurazepam;
[23] (24) Halazepam;
[24] (25) Haloxazolam;
[25] (26) Ketazolam;
[26] (27) Loprazolam;
[27] (28) Lorazepam;
[28] (29) Lormetazepam;
[29] (30) Mebutamate;
[30] (31) Medazepam;
[31] (32) Meprobamate;
[32] (33) Methohexital;
[33] (34) Methylphenobarbital (mephobarbital);
[34] (35) Midazolam;
[35] (36) Nimetazepam;
[36] (37) Nitrazepam;
[37] (38) Nordiazepam;
[38] (39) Oxazepam;
[39] (40) Oxazolam;
[40] (41) Paraldehyde;
[41] (42) Petrichloral;
[42] (43) Phenobarbital;
[43] (44) Pinazepam;
[44] (45) Prazepam;
[45] (46) Quazepam;

[46] (47) Temazepam;
[47] (48) Tetrazepam;
[48] (49) Triazolam;
[49] (50) Zaleplon;
[50] (51) Zolpidem;
(52) Zopiclone.

(b) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

(1) Cathine;
(2) Diethylpropion;
(3) Fencamfamin;
(4) Fenproporex;
(5) Mazindol;
(6) Mefenorex;
(7) Modafinil;
(8) Pemoline
(9) Phentermine
(10) Pipradol;
(11) Sibutramine;
(12) SPA [(-)dimethylamino-1,2-diphenylethane].

(c) Any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

(1) Fenfluramine.

(d) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing limited quantities of any of the following narcotic drugs, or any salts thereof:

(1) Not more than 1 milligram of Difenoxin and not less than 25 micrograms of Atropine Sulfate per dosage unit;
(2) Dextropropoxyphene.

(e) Unless specifically exempted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances, including its salts:

(1) Butorphanol; or
(2) Pentazocine.

STATEMENT OF PURPOSE:

(A) **Purpose:** Connecticut General Statutes Section 21a-243 permits the Commissioner of Consumer Protection to classify certain drugs as controlled substances. The purpose of these proposed regulations is to amend existing sections to add or remove certain drugs from the schedules of controlled substances.

(B) **Summary:** The existing regulations for the schedules of controlled substances place drugs into five categories, Schedule I through Schedule V. The federal Controlled Substances Act also establishes the same five schedules of controlled substances. To aid the Department's enforcement efforts and to further cooperation with officials from other states, as well as with federal authorities, Connecticut's controlled substance schedules need to be consistent with the federal schedules. These proposed regulations add and remove certain drugs to make Connecticut's schedules consistent with the federal schedules.

(C) **Legal Effects:** These proposed regulations alter the four lists of controlled substances set forth in sections 21a-243-7 through 21a-243-10, inclusive, of the current regulations. Drugs listed in these schedules of controlled substances are more highly regulated than other prescription drugs. These drugs have increased security and recording requirements, and violations of the associated laws yield greater criminal penalties. Therefore, the drugs added to the schedules of controlled substances by these proposed regulations will be more highly regulated, which will lead to a higher level of public safety.

PLEASE NOTE:

Within this proposed regulation, any text located within open and closed brackets that is, in turn, located wholly within open and closed parentheses, is intended to remain in the text, and not be deleted. The customary practice when editing regulations is to place any text to be deleted within open and closed brackets. However, in order to properly list the names of particular drugs, the use of brackets and parentheses is necessary. Text that is to be deleted is located solely within open and closed brackets, not also within open and closed parentheses.

Be it known that the foregoing:

[X] **Regulations** [ ] Emergency Regulations

Are:

[ ] Adopted [X] **Amended as hereinabove stated** [ ] Repealed

By the aforesaid agency pursuant to:

[X] Sections **4-168** and **21a-243** of the General Statutes and

[ ] Section _____ of the General Statutes, as amended by Public Act No. _____ of the _____ Public Acts.

[ ] Public Act No. _____ of the _____ Public Acts.

After publication in the Connecticut Law Journal on 9/14/2010 of the notice of the proposal to:

[ ] Adopt [X] **Amend** [ ] Repeal such regulations

(If applicable): [X] And the holding of an advertised public hearing on 19th day of Oct 20 10

WHEREFORE, the foregoing regulations are hereby:

[ ] Adopted [X] **Amended as hereinabove stated** [ ] Repealed

Effective:

[X] When filed with the Secretary of the State.
(OR)

[ ] The _____ day of _____, 20 _____.

In Witness Whereof:	DATE 2/1/11	SIGNED (Head of Board, Agency or Commission)	OFFICIAL TITLE, DULY AUTHORIZED COMMISSIONER
Approved by the Attorney General as to legal sufficiency in accordance with Sec. 4-169, as amended, C.G.S.:		SIGNED Joseph Rubin 2/14/11	OFFICIAL TITLE, DULY AUTHORIZED ASSOC. ATTY. GENERAL

[X] Approved

[ ] Disapproved

[ ] Disapproved in part, (Indicate Section Numbers disapproved only)

[ ] Rejected without prejudice.

By the Legislative Regulation Review Committee in accordance with Sec. 4-170, as amended, of the General Statutes.	DATE 5/26/2011	SIGNED (Clerk of the Legislative Regulation Review Committee)

Two certified copies received and filed, and one such copy forwarded to the Commission on Official Legal Publications in accordance with Section 4-172, as amended, of the General Statutes.

DATE	SIGNED (Secretary of the State)	BY

INSTRUCTIONS

One copy of all regulations for adoption, amendment or repeal, except emergency regulations, must be presented to the Attorney General for his determination of legal sufficiency. Section 4-169 of the General Statutes.

Seventeen copies of all regulations for adoption, amendment or repeal, except emergency regulations, must be presented to the standing Legislative Regulation Review Committee for its approval. Section 4-170 of the General Statutes.

Each regulation must be in the form intended for publication and must include the appropriate regulation section number and section heading. Section 4-172 of the General Statutes.

Indicate by "(NEW)" in heading if new regulation. Amended regulations must contain new language in capital letters and deleted language in brackets. Section 4-170 of the General Statutes.